Effect of Perioperative Insulin Infusion on Surgical Morbidity and Mortality: Systematic Review and Meta-analysis of Randomized Trials

Gandhi, Gunjan Y.; Murad, Hassan M.; Flynn, David N.; Erwin, Patricia J.; Cavalcante, Alexandre B.; Nielsen, Henning Bay; Capes, Sarah E.; Thorlund, Kristian; Montori, Victor M.; Devereaux, P. J.
April 2008
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p418
Academic Journal
OBJECTIVE: To conduct a systematic review and meta-analysis of randomized controlled trials (RCT5) to evaluate the effect of perioperative insulin Infusion on outcomes important to patients. PATIENTS AND METHODS: We used 6 search strategies Including an electronic database search of MEDLINE, EMBASE, and Cochrane CENTRAL, from their inception up to May 1, 2006, and Included RCT5 of perioperative insulin infusion (with or without glucose targets) measuring outcomes in patients undergoing any surgery. Pairs of reviewers working independently assessed the methodological quality and characteristics of Included trials and abstracted data on perioperative outcomes (ie, outcomes that occurred during hospitalization or within 30 days of surgery). RESULTS: We identified 34 eligible trials. In the 14 trials that assessed mortality, there were 68 deaths among 2192 patients randomized to Insulin infusion compared with 98 deaths among 2163 patients randomized to control therapy (random-effects pooled relative risk, 0.69; 95% confidence Interval [Cl], 0.51- 0.94; 99% CI, 0.46-1.04; F, 0%; 95% CI, 0.0%-47.4%). Hypoglycemia increased in the intensively treated group (20 trials, 119/ 1470 patients in insulin infusion vs 48/1476 patients in control group; relative risk, 2.07; 95% CI, 1.29-332; 99% Cl, 1.09-3.88; F, 31.5%; 95% Cl, 0.0%-590%). No significant effect was seen In any other outcomes. The available mortality data represent only 40% of the optimal information size required to reliably detect a plausible treatment effect; potential methodological and reporting biases weaken Inferences. CONCLUSION: Perioperative insulin infusion may reduce mortality but increases hypoglycemia In patients who are undergoing surgery; however, mortality results require confirmation In large and rigorous RCTs.


Related Articles

  • Effects of Hydroxylpropyl-β-Cyclodextrin on in Vitro Insulin Stability. Liefeng Zhang; Wenjie Zhu; Lingling Song; Yifan Wang; Hui Jiang; Suyun Xian; Yong Ren // International Journal of Molecular Sciences;May2009, Vol. 10 Issue 5, p2031 

    The objective of this study was to elucidate the effects of hydroxylpropyl-β- cyclodextrin (HP-β-CD) on the in vitro stability of insulin. It was found that HP-β-CD had positive effects on the stability of insulin in acid and base and under high temperature conditions. Furthermore, use...

  • Are You Waiting to Inhale? Weiger, Pamela; Whitfield, William; Farnsworth, Steve; Miller, Jacqueline; Moyer, Tina; Menninger Jr., Florian // Diabetes Health;Apr2006, Vol. 15 Issue 4, p41 

    Relates the opinions of diabetics in the U.S. on the market launching of Exubera, the noninjectible insulin from Pfizer Inc. Doubts concerning the drug; Consultation with an endocrinologist; Experience of a patient during a clinical trial on the drug.

  • Glycemic Variability in Patients with Type 2 Diabetes on Basal Insulin and Fixed Combination Oral Antidiabetic Treatment - Results of a Pilot Study. De Mattia, Giancarlo; Laurenti, Oriana; Moretti, Arianna; Mollica, Maria R. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA148 

    Type 2 diabetes (T2DM) is a progressive disease, which may eventually require insulin therapy when glycemic control fails using oral antidiabetic drugs (OADs) alone. Once-daily glargine ensures a 24-hr basal insulin replacement in T2DM patients, which can allow lower glycemic fluctuations during...

  • Pharmacotherapy-Based Problems in the Management of Diabetes Mellitus: Needs Much More to be Done! Ali, N.; Shah, S. W. A.; Khan, J.; Rehman, S.; Imran, M.; Hussian, I.; Shehbaz, N.; Jamshed, H.; Khan, S. // Journal of Young Pharmacists;2010, Vol. 2 Issue 3, p311 

    A total of 856 diabetic patients were evaluated for pharmacotherapy-based problems like for possible drug interactions, adverse drug reactions, and other mismatches, if any. Poor correlation between the advised insulin therapy and patients' fasting blood glucose levels (12%, n=103) was observed....

  • Impact of LX4211 on Cardiovascular Risk Factors in Type 2 Diabetes. Vinall, Phil // MD Conference Express;Dec2012, p26 

    The article discusses the results from the Safety and Efficacy of LX4211 with Metformin in T2DM Patients with Inadequate Glycemic Control on Metformin study by Julio Rosenstock. The study evaluates the dose-range efficacy and safety of LX4211 versus placebo from baseline to Week 12 in patients,...

  • Review: Insulin monotherapy and insulin combined with oral hypoglycemic agents provide similar glycemic control.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p62 

    The article cites a medical study which reports that insulin monotherapy and insulin combined with oral hypoglycemic agents provide similar glycemic control. Randomized controlled trials (RCTs) with ≥ 2-month follow-up compared insulin monotherapy with combinations of insulin and single or...

  • Control of Type 2 Diabetes in Obese Patients with Oral Antidiabetic Drugs after Discontinuation of Insulin Treatment. Szabo, Marcela; Peliskova, Pavlina; Matous, Milos; Kvapil, Milan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA462 

    Aim: To demonstrate that insulin-treated obese Type 2 diabetics (DM2T) can have their insulin discontinued and replaced with oral antidiabetics (OAD) with advantageous metabolic consequences. The group of 30 obese patients (18 females, 12 males with BMI 36,3±3,97 aged 56,9±1,8 years)...

  • Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus? Edward Horton // Endocrine Practice;Jul2008, Vol. 14 Issue 5, p625 

    Objective: To review the multifactorial and progressive nature of type 2 diabetes mellitus (T2DM), the consequences of its progression, and the potential of traditional and newer therapies to delay the progression of this disease.Methods: The relevant literature is reviewed, and the mechanisms...

  • Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections. Retnakaran, Ravi; Hochman, Jackie; DeVries, J. Hans; Hanaire-Broutin, Helene; Heine, Robert J.; Melki, Vincent; Zinman, Bernard // Diabetes Care;Nov2004, Vol. 27 Issue 11, p2590 

    OBJECTIVE -- Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. Thus, a comparison of efficacy between CSII...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics